FCM
CHRS icon

Flinton Capital Management’s Coherus Oncology CHRS Stock Holding History

Flinton Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$26K Hold
1,296
– – ﹤0.01% 850
2019
Q2 		$29K Hold
1,296
– – ﹤0.01% 854
2019
Q1 		$18K Buy
1,296
+272
+27% +$3.63K ﹤0.01% 853
2018
Q4 		$9K Buy
+1,024
New +$11.8K ﹤0.01% 848

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Flinton Capital Management's CHRS Position: Q3 2019 in Review

Flinton Capital Management held its Coherus Oncology (CHRS) position steady in Q3 2019 at 1,296 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #850.

Flinton Capital Management first reported a position in CHRS in Q4 2018 and has held it in 4 quarters since. The position peaked at $29K in Q2 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

  • Flinton Capital Management held 1,296 shares of Coherus Oncology worth $26K as of Q3 2019.
  • Flinton Capital Management left its Coherus Oncology share count unchanged in Q3 2019.
  • Coherus Oncology made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #850 holding.
  • Flinton Capital Management first reported a position in Coherus Oncology in Q4 2018 and has held it in 4 quarters since.
  • Flinton Capital Management's Coherus Oncology position peaked at $29K in Q2 2019.
  • 167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.